

HBV Cure Symposium Program

The HBV Cure Symposium is organized by ICE-HBV, the Peter Doherty Institute for Infection and Immunity, and the ANRS.

Conveners

Peter Revill – Doherty Institute, Sharon Lewin – Doherty Institute,
Fabien Zoulim – INSERM and ANRS

Saturday, October 5, 2019

8:30 am – 9:00 am

Keynote Address: Harvey Alter, USA
HBV – A Journey of Discovery

Chairs

Stephen Locarnini, Australia and John Tavis, USA

9:00 am – 10:15 am

Session I: Treatment Endpoints and Clinical Perspectives

Session Chairs

Joe Sasadeusz, Australia and Pietro Lampertico, Italy

- **Treatment-Endpoint Update (EASL-AASLD workshop)**
Fabien Zoulim, France

- **HBV Clinical Perspectives**
 - *Alex Thompson - Early Initiation of Therapy*
 - *Harry Janssen - Stopping Therapy*
 - *M.F. Yuen - Biomarkers*

10:15 am – 10:45 am

Refreshment Break

10:45 am – 11:15 am

Session II: Insights for HBV from HIV Cure

Session Chairs

Kasha Singh, Australia and Anna Kramvis, South Africa

- **Insights from HIV cure for HBV: beyond the Science**
Sharon Lewin, Australia

11:15 am – 12:20 pm

Session III: Latest Advances in Antiviral Therapy

Session Chairs

Massimo Levrero, Italy and Adam Gehring, Canada

- **Immunotherapy- Elimination of Infected Cells Versus Immune Control?**
Ulla Protzer, Germany
- **Direct Acting Antivirals- Can We Cure Infected Hepatocytes?**
Haitao Guo, USA
- **Towards a Curative Therapy for Hepatitis B and D Co-infected Patients: Unexpected Synergisms between IFN and the Entry Inhibitor Myrcludex B**
Stephan Urban, Germany

12:20 pm – 1:15 pm

Lunch

1:15 pm – 3:00 pm

Roundtable Discussion: New Opportunities for Combination Studies to Fast-Track HBV Cure

Moderators

Veronica Miller, USA, Seng Gee Lim, Singapore, and Harry Janssen, Canada

- **What is the Best Choice for Combination Therapy?**
Pietro Lampertico, Italy
- **Will Combination Regimen be the Same in All Patient Populations?**
Seng Gee Lim, Singapore
- **Panel Discussion: Invited Industry Professionals and Joan Block with the Hepatitis B Foundation.**

Industry Professionals; Anuj Gaggar (Gilead Sciences); Oliver Lenz (Janssen Pharmaceutica); Mike Sofia (Arbutus Biopharma); Chelsea Macfarlane (Springbank Pharmaceuticals); Andrew Vaillant (Replicor); Lu Gao (Roche Pharma Research and Early Development).

- **Closing Remarks and Signing of the Melbourne Declaration**
Peter Revill, Australia